According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Several other equities analysts have also commented on GRFS. JPMorgan Chase & Co. upgraded shares of GRIFOLS S A/S from a neutral rating to an overweight rating and increased their price objective for the company from $21.00 to $22.50 in a research report on Thursday, June 27th. BidaskClub upgraded shares of GRIFOLS S A/S from a buy rating to a strong-buy rating in a report on Saturday, August 3rd. Finally, ValuEngine lowered shares of GRIFOLS S A/S from a hold rating to a sell rating in a report on Thursday, August 1st. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $20.75.
GRFS stock opened at $21.99 on Thursday. GRIFOLS S A/S has a 52 week low of $17.42 and a 52 week high of $23.03. The company has a quick ratio of 0.95, a current ratio of 2.68 and a debt-to-equity ratio of 1.38. The company has a fifty day simple moving average of $21.90 and a two-hundred day simple moving average of $19.79. The firm has a market capitalization of $15.00 billion, a P/E ratio of 18.79, a price-to-earnings-growth ratio of 1.34 and a beta of 1.11.
Several institutional investors have recently added to or reduced their stakes in GRFS. Thomas White International Ltd. bought a new stake in shares of GRIFOLS S A/S in the 2nd quarter worth about $84,000. Advisors Asset Management Inc. lifted its holdings in shares of GRIFOLS S A/S by 40.8% in the 1st quarter. Advisors Asset Management Inc. now owns 5,108 shares of the biotechnology company’s stock worth $103,000 after acquiring an additional 1,479 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of GRIFOLS S A/S by 9.1% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,296 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 526 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of GRIFOLS S A/S by 453.8% in the 2nd quarter. Assetmark Inc. now owns 6,363 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 5,214 shares during the last quarter. Finally, First Light Asset Management LLC bought a new stake in shares of GRIFOLS S A/S in the 2nd quarter worth about $215,000. Hedge funds and other institutional investors own 19.14% of the company’s stock.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Further Reading: What causes a yield curve to invert?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.